192 related articles for article (PubMed ID: 33469680)
1. Role of ERCC5 polymorphisms in non‑small cell lung cancer risk and responsiveness/toxicity to cisplatin‑based chemotherapy in the Chinese population.
Li M; Chen R; Ji B; Fan C; Wang G; Yue C; Jin G
Oncol Rep; 2021 Mar; 45(3):1295-1305. PubMed ID: 33469680
[TBL] [Abstract][Full Text] [Related]
2. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
He C; Duan Z; Li P; Xu Q; Yuan Y
Anticancer Drugs; 2013 Mar; 24(3):300-5. PubMed ID: 23211354
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
4. Variants of ERCC5 and the outcome of platinum-based regimens in non-small cell lung cancer: a prospective cohort study.
Abdalkhalek ES; Wakeel LME; Nagy AA; Sabri NA
Med Oncol; 2022 Jul; 39(10):152. PubMed ID: 35852645
[TBL] [Abstract][Full Text] [Related]
5. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
6. [Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Zhang XR; Sun Y; Xu BH; Lin DX
Ai Zheng; 2005 Dec; 24(12):1510-3. PubMed ID: 16351803
[TBL] [Abstract][Full Text] [Related]
7.
Li M; Chen R; Ji B; Fan C; Wang G; Yue C; Jin G
Ther Adv Respir Dis; 2020; 14():1753466620918192. PubMed ID: 32401173
[TBL] [Abstract][Full Text] [Related]
8. Impact of SNP-SNP interactions of DNA repair gene
Sang L; Lv Z; Sun LP; Xu Q; Yuan Y
World J Gastroenterol; 2018 Feb; 24(5):602-612. PubMed ID: 29434449
[TBL] [Abstract][Full Text] [Related]
9. XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.
Zhang T; Sun J; Lv M; Zhang L; Wang X; Ren JC; Wang B
Asian Pac J Cancer Prev; 2013; 14(2):701-5. PubMed ID: 23621222
[TBL] [Abstract][Full Text] [Related]
10. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
Mlak R; Krawczyk P; Homa-Mlak I; Powrózek T; Ciesielka M; Kozioł P; Milanowski J; Małecka-Massalska T
Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234
[TBL] [Abstract][Full Text] [Related]
11. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
[TBL] [Abstract][Full Text] [Related]
12. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
[TBL] [Abstract][Full Text] [Related]
13. Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer.
Liu D; Wu J; Shi GY; Zhou HF; Yu Y
Genet Mol Res; 2014 Apr; 13(2):3100-7. PubMed ID: 24782167
[TBL] [Abstract][Full Text] [Related]
14. Association of ERCC5 Genetic Polymorphisms With Cirrhosis and Liver Cancer.
Yang G; Yang Y; Ma X; Huang L; Li W; Song X; Zhang H; Liu W; Lu J
Technol Cancer Res Treat; 2020; 19():1533033820943244. PubMed ID: 32812509
[TBL] [Abstract][Full Text] [Related]
15. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer.
Du Y; Su T; Zhao L; Tan X; Chang W; Zhang H; Cao G
PLoS One; 2014; 9(6):e99843. PubMed ID: 24933103
[TBL] [Abstract][Full Text] [Related]
16. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Feng J; Sun X; Sun N; Qin S; Li F; Cheng H; Chen B; Cao Y; Ma J; Cheng L; Lu Z; Ji J; Zhou Y
Acta Biochim Biophys Sin (Shanghai); 2009 May; 41(5):429-35. PubMed ID: 19430706
[TBL] [Abstract][Full Text] [Related]
17. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
[TBL] [Abstract][Full Text] [Related]
18. XPG polymorphisms and their association with lung cancer susceptibility, overall survival and response in North Indian patients treated with platinum-based doublet chemotherapy.
Lawania S; Singh N; Behera D; Sharma S
Future Oncol; 2019 Jan; 15(2):151-165. PubMed ID: 30522358
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in the ERCC5 gene and risk of esophageal squamous cell carcinoma (ESCC) in Eastern Chinese populations.
Zhu ML; Shi TY; Hu HC; He J; Wang M; Jin L; Yang YJ; Wang JC; Sun MH; Chen H; Zhao KL; Zhang Z; Chen HQ; Xiang JQ; Wei QY
PLoS One; 2012; 7(7):e41500. PubMed ID: 22848513
[TBL] [Abstract][Full Text] [Related]
20. Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy.
Chen J; Luo X; Xie G; Chen K; Jiang H; Pan F; Li J; Ruan Z; Pang X; Liang H
Medicine (Baltimore); 2016 May; 95(19):e3652. PubMed ID: 27175691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
